Functional interpretation of ovarian cancer in correlation with ISGF3 expression pattern

Purpose: Interferons are frequently used as an agent in cancer therapy because they possess tumor suppressor activity. The aim of the present work is to investigate the therapeutic role of interferon stimulated gene factor 3 (ISGF3) in different pathological stages of ovarian cancer. Materials and Methods: Sprague Dawley rats were surgically operated along with carcinogen 7,12-Dimethylbenzanthracene (DMBA) to develop ovarian cancer. Histology was used to analyze the grade of ovarian cancer. Immunohistochemistry and Western blotting technique were used to understand the expression of CK7 and ISGF3γ expression. Results: The rat incubated with carcinogen for continuous 18 and 24 weeks were able to develop low and high-grade ovarian cancer respectively. Histologically, low-grade tumor showed more transitional malignant cells while high-grade ovarian cancer showed higher number of proliferative and clumpy cells. The expression of CK7 is constantly overexpressed as tumor pregressed with band intensity of 2.7 and 4.6-fold higher in low and high-grade ovarian cancer. In contrast, interestingly ISGF3γ showed 4.3-fold higher expression in low grade ovarian cancer, but limited with only 1.7-fold higher expression in high grade ovarian cancer. Conclusion: The present results concludes that higher expression of ISGF3γ in low-grade ovarian tumor is due to suppression of tumor development, but in absence of ISGF3γ, expression of tumor development is uncontrolled.

ISGF3; Cytokeratin 7; DMBA; Ovarian cancer; Membrane accentuation.

[1] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: “Global cancer statistics, 2012”. Ca. Cancer J. Clin., 2015, 65, 87- 108.

[2] Siegel R.L., Miller K.D., Fedewa S.A., Ahnen D.J., Meester R.G.S., Barzi A., et al.: “Colorectal cancer statistics, 2017”. Ca. Cancer J. Clin., 2017, 67, 177-193.

[3] Marcus C.S., Maxwell G.L., Darcy K.M., Hamilton C.A., McGuire W. P.: “Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer”. Journal of Cancer, 2014, 5, 25-30.

[4] Bowtell D.D., Böhm S., Ahmed A.A., Aspuria P., Bast R.C., Beral V., et al.: “Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer”. Nature Reviews Cancer, 2015, 15, 668-679.

[5] Hansen J.M., Coleman R.L., Sood A.K.: “Targeting the tumour microenvironment in ovarian cancer”. Eur. J. Cancer, 2016, 56, 131-143.

[6] Coffelt S.B., de Visser K.E.: “Systemic inflammation: Cancer’s long-distance reach to maximize metastasis”. Oncoimmunology, 2016, 5, e1075694.

[7] Kitamura T., Qian B., Pollard J.W.: “Immune cell promotion of metastasis”. Nature Reviews Immunology, 2015, 15, 73-86.

[8] Svoboda M., Meshcheryakova A., Heinze G., Jaritz M., Pils D., Castillo-Tong D.C., et al.: “AIDAPOBEC-network reconstruction identifies pathways associated with survival in ovarian cancer”. Bmc Genomics, 2016, 17.

[9] Hanahan D., Weinberg R.: “Hallmarks of Cancer: The Next Gener-ation”. Cell, 2011, 144, 646-674.

[10] Darnell J., Kerr I., Stark G.: “Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins”. Science, 1994, 264, 1415-1421.

[11] Stark G., Darnell J.: “The JAK-STAT Pathway at Twenty”. Immunity, 2012, 36, 503-514.

[12] Huang Y., Jiang W., Wang Y., Zheng Y., Cong Q., Xu C.: “Enhanced efficacy and specificity of epithelial ovarian carcinogenesis by embedding a DMBA-coated cloth strip in the ovary of rat”. J. Ovarian Res., 2012, 5, 21.

[13] Wauters C.C.A.P., Smedts F., Gerrits L.G.M., Bosman F.T. Ramaekers F.C.S.: “Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary”. Hum. Pathol., 1995, 26, 852-855.

[14] Berezowski K., Stastny J.F., Kornstein M.J.: “Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma”. Mod. Pathol., 1996, 9, 426-429.

[15] Adhikary T., Wortmann A., Finkernagel F., Lieber S., Nist A., Stiewe T., et al.: “Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients”. Bmc Genomics, 2017, 18,

[16] Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al.: “Interferons at age 50: past, current and future impact on biomedicine”. Nature Reviews Drug Discovery, 2007, 6, 975- 990.

[17] Liao L., Liu Z.Z., Langbein L., Cai W., Cho E. A., Na J., et al.: “Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer”. Elife., 2018, 7, e37925.

[18] Mevissen M., Häussler M., Szamel M., Emmendörffer A., Thun-Battersby S., Löscher W.: “Complex effects of long-term 50 Hz magnetic field exposure in vivo on immune functions in femaleSprague-Dawley rats depend on duration of exposure”. Bioelectro-magnetics, 1998, 19, 259-270.

[19] Kriplani D., Patel M.: “Immunohistochemistry: A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary”. South Asian Journal of Cancer, 2013, 2, 254.

[20] Liu L., Qian J., Singh H., Meiers I., Zhou X., Bostwick D.G.: “Im-munohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis”. Arch. Pathol. Lab. Med., 2007, 131, 1290-1297.